NEW YORK (360Dx) – A new European consortium plans to remake the way in vitro diagnostics are developed and used in treating infectious diseases in a bid to combat antimicrobial resistance.
The effort, called VALUE-Dx, commenced its activities this month with a kickoff meeting held in Madrid. Backed by the European Commission, the Wellcome Trust, and private companies, VALUE-Dx will run for four years with a total budget of €14 million ($15.8 million).